Is FOLD a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,092 people get FOLD articles and Market Currents by email alert.

Get email alerts on FOLD »

HEADLINES:

Amicus Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript)
Tue, May 21
Amicus Therapeutics: The Good And The Bad
Biomed Group • Wed, May 15 • 2 Comments
Amicus Therapeutics to Present at UBS Global Healthcare Conference

GlobeNewswire (May 14, 2013)
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed
Scott Matusow • Tue, May 14 • 12 Comments
Amicus' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 10
Amicus Therapeutics Announces First Quarter 2013 Financial Results and Corporate Updates

GlobeNewswire (May 9, 2013)
Amicus Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013

GlobeNewswire (May 2, 2013)
Amicus Therapeutics to Present at 12th Annual Needham Healthcare Conference

GlobeNewswire (Apr 24, 2013)
Curing Parkinson's: The Alternative Approach - Is There Money To Be Made?
StockRiters • Thu, Apr 4 • 5 Comments
Amicus Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 12
Amicus Therapeutics Announces Full-Year 2012 Financial Results and Corporate Updates

GlobeNewswire (Mar 12, 2013)
Amicus Therapeutics to Announce Full-Year 2012 Financial Results on March 12, 2013

GlobeNewswire (Mar 7, 2013)
Amicus Therapeutics Introduces Proprietary "CHART" Platform Technology

GlobeNewswire (Mar 4, 2013)
Amicus Therapeutics to Present at Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 27, 2013)
Don't Fold On Amicus Therapeutics Just Yet
Stephen Simpson • Wed, Feb 27 • 13 Comments
Amicus: Trial Detail Fails To Halt Share Slide
EP Vantage • Tue, Feb 19 • 4 Comments
Amicus Therapeutics' CEO Presents Lysosomal Disease Network WORLD Symposium Data Highlights Conference (Transcript)
Fri, Feb 15 • 1 Comment
Amicus Therapeutics Presents Additional 6-Month Results from Phase 3 Fabry Monotherapy Study at LDN World Symposium

GlobeNewswire (Feb 15, 2013)
Amicus Therapeutics Advances Chaperone-Enzyme Replacement Therapy (ERT) Combination Platform in Pompe Disease

GlobeNewswire (Feb 14, 2013)
Amicus Therapeutics Presents Additional Results From Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease at LDN World Symposium

GlobeNewswire (Feb 13, 2013)

Don't Fold On Amicus Therapeutics Just Yet
Stephen Simpson • Wed, Feb 27 • 13 Comments

Amicus Therapeutics: The Good And The Bad
Biomed Group • Wed, May 15 • 2 Comments
Don't Fold On Amicus Therapeutics Just Yet
Stephen Simpson • Wed, Feb 27 • 13 Comments
Amicus: Trial Detail Fails To Halt Share Slide
EP Vantage • Tue, Feb 19 • 4 Comments
Orphan Drug Mania: Amicus / Migalastat HCl
Brian L. Wilson • Wed, Feb 6 • 1 Comment
Amicus Therapeutics: Explaining A 47% Loss And Why I'm Still Bullish
Ed's Stock Engineering • Tue, Jan 29 • 6 Comments
Amicus Therapeutics: One Biotech Firm Making Considerable Strides In Terms Of Pompe Disease
Matt Schilling • Fri, Jan 4 • 4 Comments
Amicus - One Final Biotech Catalyst For 2012?
Longwood Bulls • Mon, Dec 17, 2012 • 6 Comments
Amicus Soon To Release New Phase III Data
Brian L. Wilson • Fri, Dec 14, 2012 • 11 Comments
Bullish On Amicus Therapeutics
Chimera Research Group • Tue, Dec 11, 2012 • 14 Comments
Amicus Therapeutics Poised For Rebound Into December Phase III Results
Mike Havrilla • Thu, Nov 8, 2012 • 10 Comments
Amicus Therapeutics Could See A Move Like Sarepta On Positive Phase 3 Data
Scott Matusow • Tue, Oct 9, 2012 • 12 Comments
Amicus: GlaxoSmithKline And Insiders Are Heavily Buying This Stock
Scott Matusow • Thu, Aug 2, 2012 • 6 Comments
Amicus Therapeutics: Rare Disease Drug Developer Expected To Reveal Phase III Results In 3Q12
Mike Havrilla • Thu, Jul 26, 2012 • 6 Comments
A Promising $5 Biotech Stock With Major Insider Buying
Bret Jensen • Sun, Jul 1, 2012 • 7 Comments
Amicus Therapeutics: Amigal Drug Shows Promise
Zacks Investment Research • Tue, Jul 7, 2009

Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed
Scott Matusow • Tue, May 14 • 12 Comments
Curing Parkinson's: The Alternative Approach - Is There Money To Be Made?
StockRiters • Thu, Apr 4 • 5 Comments
Insider Buying Trends: Are These Cash Rich Companies Ready To Rally?
Kapitall • Tue, Feb 5
Insider Buying Trends: Are These Cash Rich Companies Ready To Rally?
Kapitall • Fri, Jan 4
Money Managers Are Selling These 7 Illiquid Stocks
Kapitall • Thu, Jan 3 • 5 Comments
Mid-Week Biopharma Catalyst Trades To Consider
Scott Matusow • Thu, Dec 13, 2012 • 7 Comments
Important Catalysts For 3 Biotech Companies
LifeSci Advisors • Fri, Dec 7, 2012 • 3 Comments
7 Low-Price Biotechs With High Positive Equity
Heisenberg Principle • Tue, Dec 4, 2012 • 5 Comments
Friday's Small Cap Biopharma Catalyst Trade And Speculation Investment List
Scott Matusow • Fri, Nov 30, 2012 • 23 Comments
Finding A Cure For Parkinson's
Jonathan Verenger • Sun, Nov 18, 2012 • 5 Comments
These 5 Insider Favorites Are Trading At Big Discounts To Target Price
Kapitall • Tue, Nov 13, 2012
5 Biotech Stocks To Go Long Now
Scott Matusow • Fri, Nov 9, 2012 • 12 Comments
5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments
Scott Matusow • Tue, Oct 9, 2012 • 14 Comments
3 Best Biotech Stocks For This Week (Part V)
Jorge Aura • Mon, Oct 8, 2012 • 2 Comments
ThinkEquity Analyst Bets On Extraordinary Science And Clinical Data
Life Sciences Report • Thu, Sep 20, 2012
Insider Buying Trends: Are These Cash-Rich Companies Ready For A Rally?
Kapitall • Tue, Sep 18, 2012 • 6 Comments
Parkinson's Disease: 3 Different Firms, 3 Novel Approaches
Shrideep Murthy • Thu, Aug 16, 2012 • 4 Comments
7 Highly Liquid Hedge Fund Stock Picks Undervalued By Target Price
Kapitall • Tue, Aug 14, 2012 • 1 Comment
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts This Year
Markus Aarnio • Fri, Aug 10, 2012 • 7 Comments
QE3, ECB Or Bust
David Brown • Wed, Aug 1, 2012 • 2 Comments

Amicus Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript)
Tue, May 21
Amicus' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 10
Amicus Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 12
Amicus Therapeutics' CEO Presents Lysosomal Disease Network WORLD Symposium Data Highlights Conference (Transcript)
Fri, Feb 15 • 1 Comment
Amicus Therapeutics' CEO Presents at 31st Annual J.P. Morgan Healthcare Conference (Transcript)
Wed, Jan 9 • 1 Comment
Amicus Therapeutics' Management Discusses at Lazard Capital Markets Healthcare Conference (Transcript)
Thu, Nov 15, 2012
Amicus' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Nov 6, 2012
Amicus Therapeutics' Management Presents at UBS Global Life Sciences Conference (Transcript)
Thu, Sep 20, 2012 • 1 Comment
Amicus Therapeutics' CEO Discusses Second Quarter Results - Earnings Call Transcript
Wed, Aug 8, 2012
Amicus Therapeutics' CEO Hosts GSK Expanded Fabry Collaboration Call (Transcript)
Sat, Jul 21, 2012
Amicus Therapeutics CEO Discusses Q3 2010 Results - Earnings Call Transcript
Mon, Nov 8, 2010
Amicus Therapeutics Agreement with GSK - Call Transcript
Sun, Oct 31, 2010
Amicus Therapeutics, Inc. Q2 2010 Earnings Call Transcript
Thu, Aug 5, 2010
Amicus Therapeutics, Inc. Q1 2010 Earnings Call Transcript
Fri, May 7, 2010
Amicus Therapeutics, Inc. Q4 2008 Earnings Call Transcript
Wed, Feb 11, 2009
Amicus Therapeutics, Inc. Q3 2008 Earnings Call Transcript
Thu, Nov 20, 2008
Amicus Therapeutics, Inc. Q2 2008 Earnings Call Transcript
Tue, Sep 2, 2008
Amicus Therapeutics Inc. Q1 2008 Earnings Call Transcript
Tue, May 13, 2008

Amicus Therapeutics to Present at UBS Global Healthcare Conference

GlobeNewswire (May 14, 2013)
Amicus Therapeutics Announces First Quarter 2013 Financial Results and Corporate Updates

GlobeNewswire (May 9, 2013)
Amicus Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013

GlobeNewswire (May 2, 2013)
Amicus Therapeutics to Present at 12th Annual Needham Healthcare Conference

GlobeNewswire (Apr 24, 2013)
Amicus Therapeutics Announces Full-Year 2012 Financial Results and Corporate Updates

GlobeNewswire (Mar 12, 2013)
Amicus Therapeutics to Announce Full-Year 2012 Financial Results on March 12, 2013

GlobeNewswire (Mar 7, 2013)
Amicus Therapeutics Introduces Proprietary "CHART" Platform Technology

GlobeNewswire (Mar 4, 2013)
Amicus Therapeutics to Present at Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 27, 2013)
Amicus Therapeutics Presents Additional 6-Month Results from Phase 3 Fabry Monotherapy Study at LDN World Symposium

GlobeNewswire (Feb 15, 2013)
Amicus Therapeutics Advances Chaperone-Enzyme Replacement Therapy (ERT) Combination Platform in Pompe Disease

GlobeNewswire (Feb 14, 2013)
Amicus Therapeutics Presents Additional Results From Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease at LDN World Symposium

GlobeNewswire (Feb 13, 2013)
Amicus Therapeutics Announces Posters and Presentations at Lysosomal Disease Network WORLD Symposium

GlobeNewswire (Feb 7, 2013)
Amicus Therapeutics to Participate in BIO CEO & Investor Conference and Leerink Swann Global Healthcare Conference

GlobeNewswire (Feb 4, 2013)
Amicus Therapeutics Provides Full-Year 2013 Financial Guidance and Strategic Outlook

GlobeNewswire (Jan 7, 2013)
Movers & Shakers: Friday’s biggest gaining and declining stocks

at MarketWatch.com (Jan 4, 2013)
Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease

GlobeNewswire (Jan 4, 2013)
Amicus Therapeutics to Present at 31st Annual J.P. Morgan Healthcare Conference

GlobeNewswire (Jan 2, 2013)
Movers & Shakers: Thursday’s movers: Apple ends in red on price cut

at MarketWatch.com (Dec 20, 2012)
After Hours: Bed Bath shares hurt, Jabil climbs after hours

at MarketWatch.com (Dec 19, 2012)
Amicus Therapeutics and GlaxoSmithKline Announce Top Line 6-Month Primary Treatment Period Results From First Phase 3 Fabry Monotherapy Study

GlobeNewswire (Dec 19, 2012)

FOLD vs. ETF Alternatives

Company Description

We are a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. Pharmacological chaperones are a novel, first-in-class approach to treating a broad range of diseases including... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 9, 5:44 PM Amicus Theraputics (FOLD): Q1 EPS of -$0.35 misses by $0.02. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, March 12, 4:27 PM Amicus Theraputics (FOLD): Q4 EPS of -$0.20 beats by $0.17. Shares -1.6% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Friday, February 15, 1:48 PM Amicus Therapeutics (FOLD -24.7%) tanks after reporting additional Stage 1 results from the ongoing Phase 3 study of oral migalastat HCl monotherapy in patients with Fabry disease. Initial top-line results previously reported in December, 2012 for the primary endpoint in Stage 1 did not meet statistical significance. The pre-specified primary and secondary analyses of the primary endpoint numerically favored migalastat HCl over placebo, but not enough to allay investor concerns. Comment! [Healthcare, On the Move]
Friday, February 15, 1:00 PM Midday top 10 gainers: URRE +21%. QLIK +18%. VBFC +17%. SAAS +16%. BIOF +15%. MM +12%. ONP +11%. BVX +12%. RBPAA +12%. XRSC +11%.
Midday top 10 losers: LOGM -29%. FOLD -24%. EHTH -22%. CJJD -17%. BOSC -12%. END -11%. ASGN -11%. RKUS -11%. IPGP -10%. WHX -10%. Comment! [On the Move]
Thursday, February 14, 9:40 AM Amicus Therapeutics (FOLD) announces positive Phase II results for its AT2220 treatment for Pompe disease, a genetic disorder that is characterized by progressive skeletal muscle weakness and respiratory insufficiency, and which affects 5,000 to 10,000 people globally. AT2220 was given in combination with enzyme replacement therapy. Amicus' shares +2.1% but down off premarket highs. (PR) Comment! [Healthcare, On the Move]
Thursday, January 17, 12:53 PM Midday top 10 gainers: NEWL +55%. KSWS +48%. SSE +44%. HMNY +21%. CALI +25%. GV +18%. FSI +14%. SHIP +14%. HILL +13%. NLS +13%.
Midday top 10 Losers: HOTR -17%. AMS -13%. PWER -8%. MY -8%. FET -7%. SZYM -8%. CLSN -8%. LEAP -7%. FOLD -7%. MELA -7%. Comment! [On the Move]
Wednesday, January 16, 5:41 PM After-hours top gainers, as of 5:15 p.m.: KSWS +57%. CBS +8%. ARQL +5%. FOLD +4%. PLXS +4%.
After-hours top losers: COLM -9%. NTI -4%. HGG -4%. SLM -3%. FET -3%. Comment! [On the Move]
Friday, January 4, 9:24 AM Amicus Therapeutics (FOLD) +10.6% premarket after the biopharma company announces positive preliminary results from all four dose cohorts in a phase 2 study of its treatment for Pompe disease, a lysosomal storage disease characterized by progressive skeletal muscle weakness and respiratory insufficiency. Comment! [Healthcare, On the Move]
Friday, January 4, 9:10 AM Premarket gainers: FOLD +10%. ALU +7%. HNR +6%. GEVA +5%.
Losers: ARAY -29%. Comment! [On the Move]
Thursday, January 3, 12:45 PM Midday top 10 gainers: SPWR +38%. VISN +30%. MDCI +20%. FORD +20%. BGMD +19%. TSL +19%. CRDC +19%. FOLD +19%. TELK +18%. JASO +16%.
Midday top 10 Losers: LPH -73%. ALLT -23%. MLNX -14%. FDO -12%. AMPL -12%. TRIT -11%. PKT -10%. SSI -9%. LODE -9%. HPJ -9%. 1 Comment [On the Move]
Thursday, January 3, 9:10 AM Premarket gainers: BGMD +22%. SPWR +16%. ALU +10%. CBMX +10%. FOLD +8%. TASR +6%. LDK +6%. ZGNX +5%.
Losers: MLNX -18%. ALLT -10%. FDO -10%. KERX -6%. BIIB -6%. Comment! [On the Move]
Wednesday, December 26, 2012, 5:57 PM After-hours top gainers, as of 5:30 p.m.: MACK +5%. CLDX +4%. FOLD +4%. IDIX +3%. NBIX +2%.
After-hours top losers: AMBA -2%. DGAZ -2%. MRVL -2%. DNDN -2%. PRSS -1%. 1 Comment [On the Move]
Thursday, December 20, 2012, 12:45 PM Midday top 10 gainers: ROMA +65%. ACFC +51%. NYX +33%. AMPL +37%. ELOQ +31%. SINO +22%. BNSO +21%. DYNT +22%. SQNS +14%. RAD +16%.
Midday top 10 Losers: CCU -60%. FOLD -45%. BOSC -19%. MDRX -13%. UNXL -13%. GBX -11%. QUAD -11%. ARII -11%. PTEK -10%. GBR -10%. Comment! [On the Move]
Thursday, December 20, 2012, 9:10 AM Premarket gainers: ROMA +57%. NYX +40%. ELOQ +30%. RAD +16%. ILMN +9%. VVUS +8%. NDAQ +7%. ARRS +6%. ICE +6%. JBL +5%.
Losers: FOLD -44%. MDRX -16%. OSIR -10%. NBG -5%. BBBY -5%. 2 Comments [On the Move]
Wednesday, December 19, 2012, 5:40 PM After-hours top gainers, as of 5:15 p.m.: SD +8%. APOL +7%. TTWO +6%. JBL +6%. GNCMA +5%.
After-hours top losers: FOLD -52%. RGR -7%. VRTX -6%. HMA -5%. ACN -5%. 3 Comments [On the Move]
Wednesday, December 19, 2012, 4:34 PM Amicus Therapeutics (FOLD) and GlaxoSmithKline (GSK) announce results from the Phase III study of its investigational oral migalastat HCl monotherapy in patients with Fabry disease, noting the pre-designated primary endpoint was not achieved. FOLD -50%, GSK -0.7% AH. 4 Comments [Healthcare, On the Move]

foldholder
$FOLD when are results coming in april?
Mar 20, 9:19 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ed's Stock Engineering
Nice to see $FOLD back over $4... Let's hope this is a sign of things to come. http://tinyurl.com/bgdjg79
Feb 12, 3:25 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LEIGHDIST
due to what has happened to $FOLD would this be a good time to get in
Jan 7, 12:15 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Perkins Cove
$FOLD is slowly folding. ($3.12) When looking for a bounce play, watch carefully in pre mkt. (3.05 to 3.40 was the play)
12/20/12
Reply (4)

• !Report Abuse
View all 4 replies
Perkins Cove: $FOLD is now $3.09 and dropping. ( Capstone downgrades $FOLD to hold, pt 3.)
12/20/12
• !Report Abuse
Perkins Cove: Bounce players....think "pennant". The best movement is early.
12/20/12
• !Report Abuse
Add a reply...

140 characters

FortSumter
$FOLD and $ONTY Longs in those will be able to offset giant gians in others (hopefully). Both down >50% today on bad drug trials.
12/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

foldholder
$FOLD. Any reason why the stock is going down given the 2 catalyst coming in this month? Is it safe to hold this stock?
12/4/12
Reply (9)

• !Report Abuse
View all 9 replies
John Rayhall: Biotechs are volatie not for the faibt of heart as you know. For example I own CLDX which has beeb sold off from a 6.71 high to around 5.50
12/10/12
• !Report Abuse
John Rayhall: the boom they release good data today and it pops 25%. I think the same will happen with FOLD. Fingers crossed. *Faint and been
12/10/12
• !Report Abuse
Add a reply...

140 characters

Ghostrider1
$FOLD Hi Scott. Are you holding until news? BTW is any news expected on the 30th of Nov. Thanks. (Fellow Drummer here:)
11/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
$FOLD $6.04 #bigtime-winning
11/28/12
Reply (11)

• !Report Abuse
View all 11 replies
Scott Matusow: nope, not over, and I maintain my opinion of a double on good data from the 011 12 month study. It's my opinion that there was
Jan 26, 6:17 PM
• !Report Abuse
Scott Matusow: a control group issue with asymptomatic women, which is why the company says " we are moving forward towards filing an NDA."
Jan 26, 6:18 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$FOLD - shorter short term target of $6 complete, Next stop - if 011 P3 data good = $10
11/28/12
Reply (9)

• !Report Abuse
View all 9 replies
tomfalbo: great call Scott
11/29/12
• !Report Abuse
Pescoe: Scott, are you still have FOLD? What do think of data so far?
12/11/12
• !Report Abuse
Add a reply...

140 characters

smokeyRose
$FOLD (Biotechnology) > 5.43 up 0.52 + 10.59% vol1.0M avg vol 506.9K
11/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Scott Matusow
$FOLD $6.04 #bigtime-winning
11/28/12
Reply (11)

• !Report Abuse
View all 11 replies
Scott Matusow: nope, not over, and I maintain my opinion of a double on good data from the 011 12 month study. It's my opinion that there was
Jan 26, 6:17 PM
• !Report Abuse
Scott Matusow: a control group issue with asymptomatic women, which is why the company says " we are moving forward towards filing an NDA."
Jan 26, 6:18 PM
• !Report Abuse
Add a reply...

140 characters

Perkins Cove
$FOLD is slowly folding. ($3.12) When looking for a bounce play, watch carefully in pre mkt. (3.05 to 3.40 was the play)
12/20/12
Reply (4)

• !Report Abuse
View all 4 replies
Perkins Cove: $FOLD is now $3.09 and dropping. ( Capstone downgrades $FOLD to hold, pt 3.)
12/20/12
• !Report Abuse
Perkins Cove: Bounce players....think "pennant". The best movement is early.
12/20/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$FOLD - shorter short term target of $6 complete, Next stop - if 011 P3 data good = $10
11/28/12
Reply (9)

• !Report Abuse
View all 9 replies
tomfalbo: great call Scott
11/29/12
• !Report Abuse
Pescoe: Scott, are you still have FOLD? What do think of data so far?
12/11/12
• !Report Abuse
Add a reply...

140 characters

foldholder
$FOLD. Any reason why the stock is going down given the 2 catalyst coming in this month? Is it safe to hold this stock?
12/4/12
Reply (9)

• !Report Abuse
View all 9 replies
John Rayhall: Biotechs are volatie not for the faibt of heart as you know. For example I own CLDX which has beeb sold off from a 6.71 high to around 5.50
12/10/12
• !Report Abuse
John Rayhall: the boom they release good data today and it pops 25%. I think the same will happen with FOLD. Fingers crossed. *Faint and been
12/10/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$FOLD likely to break $5.50 today in my strong opinion
11/27/12
Reply (6)

• !Report Abuse
View all 6 replies
jtank: Thanks for the link. I kinda wish I hadn't written 7.50 covered calls against my position - i feel like i might miss out on maximal profit.
11/28/12
• !Report Abuse
John Rayhall: We'll see what happens but I guess it can't hurt. Hopefully they won't sell the news which I don't think they will.
11/28/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$LGND $19.05 alerted at $16.60 $BGMD $1.35 alerted at $1.05 $AVEO $6.80 alerted at $6.60 $FOLD $4.85 alerted at $4.35
11/23/12
Reply (4)

• !Report Abuse
View all 4 replies
blakhalo: CPRX $.52 alerted at $1.88 -/+
11/26/12
• !Report Abuse
Scott Matusow: blak, u must lose money in the market -- I also gave a price target of $2.25 after financing -- that's on traders, now learn to make money
11/26/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
My new article out @ http://seekingalpha.com/a/lb6d $BSDM $FOLD $SRPT $IRWD $THLD
11/9/12
Reply (12)

• !Report Abuse
View all 12 replies
drpharm: its legitimate, i have to wait until tomorrow, buts its okay, im on the upside overall because of your picks. its just a flesh wound haha
11/14/12
• !Report Abuse
Scott Matusow: cool that is very MUCH a relief to hear!
11/14/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$BSDM, I like that one. $FOLD doing well. both should make nice moves.
11/9/12
Reply (2)

• !Report Abuse
View all 2 replies
Noreika: Nice call on FOLD Scott.
11/9/12
• !Report Abuse
Scott Matusow: ty now
11/9/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$FOLD too undervalued here, I still maintain double on P3 so I bought a nice big chunk of it, stock now has option chain - POSITIVE
11/8/12
Reply (3)

• !Report Abuse
View all 3 replies
investlearner: Thank you scott. Are you planning for any updates in coming weeks with new picks?
11/8/12
• !Report Abuse
Scott Matusow: yes
11/8/12
• !Report Abuse
Add a reply...

140 characters

Joe Springer
Insider's showing their hands: http://bit.ly/TuYnnJ $MNKD $ARIA $VRTX $OREX $FOLD $ZLTQ $ISIS
10/17/12
Reply (4)

• !Report Abuse
View all 4 replies
mark woods: Did you say FOLD had strong insider selling or buying?
10/18/12
• !Report Abuse
Joe Springer: Hey Mark - Buying http://bit.ly/U9xCdG
10/18/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$FOLD doing a lot better than I ever thought today. show us people like that one, and they should, the risk should be manageable
10/9/12
Reply (3)

• !Report Abuse
View all 3 replies
21mark: Thanks Scott, from a former Southern Nevada resident, Now living in Oregon. I love reading your insight and so does my trading account.
10/11/12
• !Report Abuse
Scott Matusow: u are welcome
10/11/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
10/31/12: FOLD Phase 2 Trial Update for AMIGAL and Phase 2 Trial update for AT2220 @ http://bit.ly/SKBUrQ
10/9/12
Reply (5)

• !Report Abuse
View all 5 replies
barcaboyvn: I hold some IPCI, I hope Focalin XR this month, mid Nov at the latest!
10/9/12
• !Report Abuse
sapaburu: It's my largest position, kind of risky but I believe in Odidi the magician (remember Biovail!)
10/9/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$FOLD Chart and opinion, Further $ATRS commentary. To start, I remark I am still bullish on Antares @ http://bit.ly/Q0yD3t
10/5/12
Reply (3)

• !Report Abuse
View all 3 replies
Scott Matusow: yes
10/5/12
• !Report Abuse
sheldond: Love it Scott, Great ideas here about Fold. I hold the Fold and so should you.
10/6/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I am buying $FOLD, I think it has great shot to be a double from here. P3 Data soon for Fabry disease, $GSK owns 20% of CO. #AMICUS
10/4/12
Reply (2)

• !Report Abuse
View all 2 replies
IronmanVR4: Scott ATRS has moved as much as I thought it would..any reason?
10/4/12
• !Report Abuse
Scott Matusow: pinned near 4 for offering
10/4/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$CRTX and $FOLD looking good.
8/14/12
Reply (5)

• !Report Abuse
View all 5 replies
robnjit: Scott. Agree. Wild ride. I had 10k worth of shares. Happy days when since you made the recommendation!
8/15/12
• !Report Abuse
reachmygoals1: scott, i added crtx today. it looks like high potential for a run with panel votes on thursday. company has lots of cash
9/11/12
• !Report Abuse
Add a reply...

140 characters

FOLD Amicus Therapeutics, Inc.

FOLD

Amicus Therapeutics, Inc.